Inspire Medical Q2 revenue down 7.6% to $200.6M; raises FY2026 guidance; announces Project Horizon restructuring

Inspire Medical Systems, Inc.

Q2 revenue $200.6M (-7.6% YoY); diluted EPS $0.01, adjusted diluted EPS $0.14.
Gross margin 85.5% (+150 bps); operating cash flow $23.2M vs $2.7M prior year.
Raised FY2026 revenue guidance to $835M-$875M; adjusted diluted EPS guidance $1.05-$1.45.
Announced Project Horizon restructuring to generate $30M annualized growth investment capacity; expects $20M-$25M pre-tax charges.
Cash and investments $415.2M as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.